



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

April 29, 2024

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Annual Disclosure regarding non-applicability of SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021

Dear Sir/Madam,

This is with reference to the SEBI circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 in respect of fund raising by issuance of Debt Securities by Large Entities, please find enclosed the annual disclosure for the financial year ended 2023-24 in the prescribed format in the said circular. We would like to confirm that for the financial year ended March 31, 2024, our Company is '**Not a Large Corporate**' as per the framework provided in the aforesaid Circular.

Kindly take the same on your record.

Yours faithfully,
For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary and Compliance Officer



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

1. Name of Company: Jagsonpal Pharmaceuticals Limited
2. CIN: L74899DL1978PLC009181
3. Report filed for FY: 2023-24
4. Details of the current block:

Sr. No.	Particulars	Details
1.	2 year block period	(T) FY 2023-24 (T+1) FY 2024-25
2.	Incremental borrowing done in FY 2022-23 (a)	NIL
3.	Mandatory borrowing to be done through debt securities in FY 2022-23 (b) = (25% of a)	NIL
4.	Actual borrowing done through debt securities in FY 2022-23 (c)	NIL
5.	Shortfall in the borrowing through debt securities, if any, for FY 21-22 carried forward to FY 2022-23 (d)	NIL
6.	Quantum of (d), which has been met from (c) (e)	NIL
7.	Shortfall, if any, in the mandatory borrowing through debt securities for FY 2022-23 {after adjusting for any shortfall in borrowing for FY 21-22 which was carried forward to FY 2022-23} (t) = (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	NIL

5. Details of penalty to be paid, if any, in respect to previous block:

Sr. No.	Particulars	Details
1.	2 year block period	(T-1) FY 2022-23 (T) FY 2023-24
2.	Amount of fine to be paid for the block, if applicable	NIL

Abhishek Joshi
Company Secretary and Compliance Officer
Contact No.: 0124-4406710

Ashish Lakhotia
Chief Financial Officer
Contact No.: 0124-4406710